Author:
Chen Yu-Mu,Fang Ying-Tang,Lai Chien-Hao,Rau Kun-Ming,Huang Cheng-Hua,Chang Huang-Chih,Chao Tung-Ying,Tseng Chia-Cheng,Fang Wen-Feng,Wang Chin-Chou,Chen Yung-Che,Chung Yu-Hsiu,Wang Yi-Hsi,Su Mao-Chang,Liu Shih-Feng,Huang Kuo-Tung,Chen Hung-Chen,Chang Ya-Chun,Chang Yu-Ping,Lin Meng-Chih
Publisher
Public Library of Science (PLoS)
Reference43 articles.
1. Lung cancer incidence trends among men and women—United States, 2005–2009;SJ Henley;MMWR Morbidity and mortality weekly report,2014
2. Lung cancer and prognosis in taiwan: a population-based cancer registry;BY Wang;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2013
3. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC);G Chen;Annals of oncology: official journal of the European Society for Medical Oncology / ESMO,2013
4. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS);S Thongprasert;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2011
5. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;JC Yang;The Lancet Oncology,2015
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献